Consensus IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Market Closed - Nasdaq Other stock markets 04:00:01 2024-05-31 pm EDT			5-day change	1st Jan Change
8.31 ^USD	-4.59%		-12.98%	-.--%

May. 09	RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk	MT
May. 08	Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000	MT

Evolution of the average Target Price on IGM Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

61e8bc790acc10f34cf22.1NSKAf2TLHdZ6ozHbu8noGi9Phn54sOh6x5qcan-Bio.p4vyebSkSC0umP-uPIhC2C7xfEq00u6UgkkLBc6VVhrissVOtqJnJQug2Q~ea663549358bcf481a715b03851e33f1

Analyst Recommendations on IGM Biosciences, Inc.

RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk	May. 09	MT
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating	Mar. 12	MT
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept	Feb. 09	MT
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20	Dec. 15	MT
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11	Dec. 07	MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating	Dec. 06	MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk	Dec. 06	MT
Morgan Stanley Adjusts IGM Biosciences Price Target to $8 From $15, Maintains Equal Weight Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on IGM Biosciences to $11 From $17, Keeps Buy Rating	Nov. 15	MT
Stifel Trims IGM Biosciences' Price Target to $25 From $26, Keeps Buy Rating	Nov. 14	MT
RBC Cuts Price Target on IGM Biosciences to $8 From $11, Keeps Sector Perform, Speculative Risk	Nov. 14	MT
Wedbush Lowers IGM Biosciences' Price Target to $16 From $19, Keeps Outperform Rating	Nov. 14	MT
HC Wainwright Adjusts IGM Biosciences' Price Target to $17 From $22, Keeps Buy Rating	23-08-07	MT
Morgan Stanley Adjusts Price Target on IGM Biosciences to $15 From $20, Maintains Equal-Weight Rating	23-08-07	MT
RBC Cuts Price Target on IGM Biosciences to $11 From $17, Maintains Sector Perform Rating, Speculative Risk Qualifier	23-08-07	MT
Wedbush Cuts IGM Biosciences' PT to $19 From $37, Notes Focus of Aplitabart in mCRC, Removes Potential Imvotamab Oncology Revenues; Keeps Outperform Rating	23-08-04	MT
JPMorgan Adjusts Price Target on IGM Biosciences to $19 From $26, Maintains Neutral Rating	23-05-16	MT
RBC Cuts Price Target on IGM Biosciences to $17 From $21, Maintains Sector Perform, Speculative Risk	23-05-15	MT
Wedbush Lowers IGM Biosciences' Price Target to $37 From $41, Adjusts Future Financing Assumptions; Keeps Outperform Rating	23-05-15	MT
Truist Securities Lowers Price Target on IGM Biosciences to $25 From $37, Maintains Buy Rating	23-04-04	MT
JPMorgan Chase Adjusts Price Target on IGM Biosciences to $26 From $27, Maintains Neutral Rating	23-04-03	MT
Morgan Stanley Adjusts Price Target on IGM Biosciences to $20 From $30, Maintains Equal-Weight Rating	23-04-03	MT
HC Wainwright Adjusts Price Target on IGM Biosciences to $22 From $45, Maintains Buy Rating	23-04-03	MT
Wedbush Cuts IGM Biosciences' Price Target to $41 From $58, Adjusts Assumptions for IGM-8444, Imvotamab; Keeps Outperform Rating	23-04-03	MT
RBC Cuts Price Target on IGM Biosciences to $21 From $24, Keeps Sector Perform Rating, Speculative Risk Qualifier	23-03-31	MT